Potentiation of the anticancer drug BCNU by AMD3100 has also been shown with the intracranially implanted U87 human glioblastoma, though the mechanism for this may have involved abrogation of the survival function of the SDF-1/CXCR4 pathway in the tumour cells (Redjal et al, 2006) rather than prevention of revascularisation after irradiation. Here, CXCR4 is linked to neoplasm.